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Abstract
Background: Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disorder of the central nervous
system (CNS) and is the leading cause of nontraumatic disability among young adults. Activated microglial cells are
important effectors of demyelination and neurodegeneration, by secreting cytokines and others neurotoxic agents.
Previous studies have demonstrated that microglia expresses ATP-sensitive potassium (KATP) channels and its
pharmacological activation can provide neuroprotective and anti-inflammatory effects. In this study, we have
examined the effect of oral administration of KATP channel opener diazoxide on induced experimental autoimmune
encephalomyelitis (EAE), a mouse model of MS.
Methods: Anti-inflammatory effects of diazoxide were studied on lipopolysaccharide (LPS) and interferon gamma
(IFNg)-activated microglial cells. EAE was induced in C57BL/6J mice by immunization with myelin oligodendrocyte
glycoprotein peptide (MOG35-55). Mice were orally treated daily with diazoxide or vehicle for 15 days from the day
of EAE symptom onset. Treatment starting at the same time as immunization was also assayed. Clinical signs of
EAE were monitored and histological studies were performed to analyze tissue damage, demyelination, glial
reactivity, axonal loss, neuronal preservation and lymphocyte infiltration.
Results: Diazoxide inhibited in vitro nitric oxide (NO), tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-
6) production and inducible nitric oxide synthase (iNOS) expression by activated microglia without affecting
cyclooxygenase-2 (COX-2) expression and phagocytosis. Oral treatment of mice with diazoxide ameliorated
EAE clinical signs but did not prevent disease. Histological analysis demonstrated that diazoxide elicited a
significant reduction in myelin and axonal loss accompanied by a decrease in glial activation and neuronal
damage. Diazoxide did not affect the number of infiltrating lymphocytes positive for CD3 and CD20 in the
spinal cord.
Conclusion: Taken together, these results demonstrate novel actions of diazoxide as an anti-inflammatory agent,
which might contribute to its beneficial effects on EAE through neuroprotection. Treatment with this widely used
and well-tolerated drug may be a useful therapeutic intervention in ameliorating MS disease.
Keywords: Diazoxide, experimental autoimmune encephalomyelitis, KATP channel, microglia, multiple sclerosis,
neuroprotection
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Background
Multiple Sclerosis (MS) is a chronic autoimmune,
inflammatory and degenerative disease of the central
nervous system (CNS) that causes significant disability.
Current drugs improve the course of the disease but
with limited efficacy, serious side effects and inconveni-
ent routes of administration. For these reasons, there is
a need to develop more efficacious drugs (targeting
inflammation and also neurodegeneration) that are safer
(avoiding life-threatening adverse events, fatal infections
or cancer), have non-serious adverse events that impair
quality of life (e.g., flu-like symptoms), can be adminis-
tered orally and have a good profile for eventual combi-
nation therapy.
Microglial cells, the resident macrophage populations
in the CNS, sustain and propagate inflammation within
the CNS through antigen and/or cytokine/chemokine
secretion, which are important effectors of the demyeli-
nation and neurodegeneration described in MS [1]. Peri-
vascular microglia act as antigen-presenting cells to
myelin-specific T cells and promote the CNS-confined
inflammatory process. Once the process is initiated, par-
enchymal microglial cells are activated and elicit myelin
damage and neurodegeneration by secreting pro-inflam-
matory and neurotoxic factors such as tumor necrosis
factor alpha (TNF-a), prostaglandins, interleukin-6 (IL-
6), nitric oxide (NO) or reactive oxygen species (ROS)
[2,3]. Thus, microglial cells are a potential therapeutic
target in inflammatory CNS disorders such as MS.
Potassium (K+) channel modulation is widely pursued
as novel pharmaceutical strategy for the treatment of
neurological disorders and autoimmune diseases [4]. In
MS, activation on T cells depends on K+ channel and
selective targeting of two-pore domain K+ channels
(K2P5.1), voltage-gated K
+ channel KV1.3 and calcium-
activated K+ channel IKCa1 have been proposed for the
treatment of CNS inflammation and degeneration [5-7].
ATP-sensitive K+ (KATP) channels are large hetero-octa-
meric complexes consisting of four pore-forming
inward-rectifying K+ subunits (Kir6.x) and four regula-
tory sulfonylurea receptor (SURx) subunits [8]. They are
considered metabolic sensors that couple cellular energy
metabolism to membrane excitability by regulating
potassium flux. These channels act as energy sensors of
ATP production and are believed to regulate various
physiological functions, such as muscle contraction and
insulin secretion, by coupling cell metabolism to mem-
brane potential [9-11]. KATP channels are also present at
the mitochondrial inner membrane (mito-KATP) and
they participate in the regulation of mitochondrial
volume and membrane potential. Furthermore, their
activity is related to electronic transport, metabolic
energy, ROS production and mitochondrial welfare
[12,13]. KATP channels are found in a range of tissues
and they are also widely expressed in various brain
regions, where they couple electrical activity of the neu-
ron to its metabolic state, and modulate neuronal excit-
ability in different physiological and pathological
conditions [14-16].
We previously reported that activated microglia in a
rat model of neurodegeneration and in postmortem
samples of patients with Alzheimer’s disease (AD)
strongly expressed KATP channel SUR components simi-
lar to those in neurons and pancreatic beta-cells [17]. In
this context, controlling the extent of microglial activa-
tion and neuroinflammation may offer prospective clini-
cal therapeutic benefits for inflammation-related
neurodegenerative disorders. Other authors have docu-
mented that pharmacological activation of KATP chan-
nels can exert neuroprotective and anti-inflammatory
effects on the brain against ischemia, trauma and neuro-
toxicants [18-21]. Therefore, the expression of KATP
channels by activated microglia indicates that KATP
channel openers (KCOs), such as diazoxide, could be
used as therapeutic agents to treat inflammatory and
neurodegenerative diseases like MS.
Diazoxide (7-chloro-3-methyl-4H-1,2,4-benzothiadia-
zine 1,1-dioxide) is a well-known small molecule that
activates KATP channels in the smooth muscle of blood
vessels and pancreatic beta-cells by increasing mem-
brane permeability to potassium ions. It is structurally
related to the thiazide diuretics, but does not possess
any discernible diuretic activity. Its binding site is
located on other regions of the SUR protein than the
site for other KCOs and binding with similar affinities
to SUR1 and SUR2B [22]. Diazoxide-induced hyperpo-
larization of cell membranes prevents calcium entry via
voltage-gated Ca2+ channels (VGCCs), resulting in
vasorelaxation and the inhibition of insulin secretion
[23,24]. As a consequence, diazoxide increases the con-
centration of plasma glucose and produces a fall in
blood pressure by a vasodilator effect on the arterioles
and a reduction in peripheral resistance. Due to these
actions, diazoxide has been approved and used since the
1970s for treating malignant hypertension and hypogly-
cemia in different European countries, the United States
and Canada [25,26].
Others authors found that diazoxide-mediated cyto-
protection is independent of the conductance of the
mito-KATP channel inhibiting succinate oxidation and
succinate dehydrogenase activity [27]. These data impli-
cate a direct mitochondrial respiratory inhibition-trig-
gered ROS signaling mechanism in the protection of
tissues by diazoxide [28].
The aims of the present study were to: (a) analyze the
expression of KATP channels on microglial cells and
whether its pharmacological activation by diazoxide
modulates the release of inflammatory mediators, and
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(b) study the effects of diazoxide oral administration on
myelin oligodendrocyte glycoprotein peptide (MOG35-
55)-induced experimental autoimmune encephalomyelitis
(EAE), a murine model of MS.
Methods
Primary cell culture and cell line
The mouse microglial cell line BV-2 was purchased at
the Istituto Nazionale per la Ricerca sul Cancro (IST,
Genova, Italy), while primary glial cultures were
obtained from 2- to 4-day old C57BL/6J mice as
described previously by Saura et al. [29].
Mice
Female C57BL/6J mice, 8 to 10 weeks of age, were pur-
chased from Charles River (Sulzfeld, Germany) and
maintained on a 12:12 h light:dark cycle, with standard
chow and water freely available. Animals were handled
according to European legislation (86/609/EEC) and all
manipulations were performed in accordance with Eur-
opean legislation (86/609/EEC). All efforts were made to
minimize the number of animals and their suffering
during the experiments, and procedures were approved
by the Ethics Committee of the University of Barcelona
under the supervision of the Generalitat of Catalunya,
Spain.
Reagents
Diazoxide was purchased from Sigma-Aldrich (St. Louis,
MO, USA). Stock solutions (50 mM) of diazoxide were
prepared in dimethyl sulfoxide (DMSO, Sigma-Aldrich).
Solutions for cell treatment were prepared by diluting
stock solutions in culture media immediately before
being added to the cells (DMSO concentration: 0.5%).
Solutions for animal treatment were prepared by dilut-
ing stock solution in water every day of the treatment
(DMSO concentration: 0.3%).
Cell culture and treatment
For primary mixed glial cultures, cells were seeded at a
density of 4 × 105 cells/mL and cultured in Dulbecco’s
modified Eagle medium-F-12 nutrient mixture supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), 0.1% penicillin-streptomycin and 0.5 μg/mL
amphotericin B (Fungizone®) (all from Gibco Invitrogen,
Paisley, Scotland, UK). Cells were maintained at 37°C in
a 5% CO2 humidified atmosphere. Medium was replaced
every 7 days. After 19 to 21 days in vitro (DIV), micro-
glia were isolated as described by Saura and collabora-
tors [29]. Cultures obtained following this method
contained > 98% of microglia. The following day, mixed
glial and microglial cultures were treated with different
concentrations of diazoxide 30 min before stimulation
with lipopolysaccharide (LPS) (E. coli serotype 026:B6)
100 ng/mL and recombinant mouse interferon gamma
(IFNg) (both from Sigma-Aldrich, St. Louis, MO, USA)
10 pg/mL. As control, unstimulated cells and unstimu-
lated cells pretreated with highest diazoxide concentra-
tion (100 μM) were used. Both contained the same final
concentration of vehicle as the compound-containing
wells.
BV-2 cells were cultured in RPMI-1640 medium
(Gibco Invitrogen, Paisley, Scotland, UK) supplemented
with 10% FBS and 0.1% penicillin-streptomycin. Cells
were maintained at 37°C in a 5% CO2 humidified atmo-
sphere. BV-2 cells were seeded at a density of 5 × 104
cells/mL. The following day, cells were treated with
diazoxide 30 min before stimulation with LPS 100 ng/
mL and IFN-g 50 pg/mL. Control wells contained the
same final concentration of vehicle as the compound-
containing wells.
Culture supernatants of BV-2 and primary cells were
collected 24 h after LPS/IFN-g stimulation and stored at
-20°C until assayed for nitrites, TNF-a and IL-6 content.
Cell viability after treatment was determined by the 3-
(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) reduction method.
Nitrite, TNF-a and IL-6 quantification
Nitrite levels were quantified by the Griess reaction.
Briefly, 50 μL of culture medium was mixed in a 96-well
plate with 25 μL of Griess reagent A (sulfanilamide) and
25 μL of reagent B (N-1- naphthyl ethylene -diamine).
After color development (10 min at 23 to 25°C), samples
were measured at 540 nm on a microplate reader (Bio-
Tek ELX800, BioTek Instruments Inc., Vermont, USA).
Nitrite concentration was determined from a sodium
nitrite standard curve. The amount of TNF-a and IL-6
released into the culture medium was determined using
an Enzyme-linked immunosorbent assay (ELISA) kit
specific for mouse TNF-a (Murine TNF-a ELISA Devel-
opment Kit, Peprotech, Rocky Hill, NJ, USA) and for
mouse IL-6 (Mouse IL-6 Ready-SET-Go!®, eBioscience,
San Diego, CA, USA) according to the manufacturer’s
instructions.
Immunofluorescence cell staining
BV-2 cells were activated with LPS/IFN-g for 24 h, as
described above. Then, cells were fixed with cold metha-
nol (-20°C) for 5 minutes. Cultures were blocked in
phosphate buffered saline (PBS) solution containing 10%
donkey serum (Sigma-Aldrich, St. Louis, MO, USA) and
1% bovine serum albumin (BSA) (VWR International
Ltd, UK) for 20 minutes. Cells were then incubated with
primary antibodies anti-Kir6.1 and anti-Kir6.2 (1:300
dilution, Alomone, Jerusalem, Israel), anti-CD11b (1:500
dilution, Serotec, Oxford, England, UK) at 4°C over-
night, followed by secondary antibodies Alexa®488 and
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596 (1:500, Molecular Probes, Invitrogen, Eugene, OR,
USA) for 1 h in blocking solution. Slides were mounted
in ProLong Gold antifade medium (Molecular Probes,
Invitrogen, Eugene, OR, USA) and images were acquired
by SP1 confocal microscope (Leica Microsystems
GmbH, Wetzlar, Germany), located at the Institut de
Biologia Molecular de Barcelona, Microscopy Unit, Parc
Científic de Barcelona, Barcelona, Spain.
Phagocytosis assay
The phagocytic ability of microglia was determined by
the uptake of 2-μm red fluorescent microspheres (Mole-
cular Probes, Invitrogen, Eugene, OR, USA) by BV-2
cells. Cells were treated with diazoxide 100 μM and acti-
vated with LPS/IFN-g, as described above, and then
incubated with microspheres at a concentration of
0.01% for 30 min in the dark at 37°C and 5% CO2. Cells
were rinsed twice in PBS solution, pelleted at 1,000 g for
5 min and resuspended in 300 μL PBS. Cells were kept
on ice and analyzed by flow cytometry. The single-cell
fluorescent population was selected on a forward-side
scatter scattergram using an Epics XL flow cytometer
(Coulter Corporation, Miami, Florida) located at Techni-
cal and Scientific Center-University of Barcelona, Parc
Científic Barcelona, Barcelona, Spain.
Some samples were fixed with 3% paraformaldehyde
solution and stained using FITC conjugated anti-a-
tubulin antibody (Sigma-Aldrich, St. Louis, MO, USA)
and Hoechst 34580 (Molecular Probes, Invitrogen,
Eugene, OR, USA) nuclear staining for image
acquisition.
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) reduction method
MTT reduction assay was used as an indicator of cell
viability. MTT (Sigma-Aldrich, St. Louis, MO, USA) was
added to a well at a final concentration of 0.5 mg/mL.
After MTT incubation at 37°C, DMSO was added and
cells were gently resuspended. Absorbances at 560 and
620 nm were recorded with a microplate reader (BioTek
ELX800, BioTek Instruments Inc., Vermont, USA).
Isolation of total protein
For spinal cord total protein extraction, tissue (100 mg)
was placed into a 1.5-mL microtube on ice containing
500 μL ice-cold RIPA extraction buffer (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with complete pro-
tease inhibitor cocktail tablets (Roche Diagnostics, Basel,
Switzerland). The sample was homogenized with a pip-
ette tip on ice for 30 min. The homogenate was centri-
fuged at 6000 g for 15 min at 4°C. The supernatant was
separated and stored at -80°C until use. For isolation of
total proteins from cell cultures, after a cold PBS wash,
total proteins were recovered in 100 μL per well of
RIPA buffer supplemented with complete protease inhi-
bitor cocktail tablets. The samples were sonicated and
stored at -80°C. Protein amount was determined by the
Lowry assay (Total Protein Kit micro-Lowry, Sigma-
Aldrich, St. Louis, MO, USA).
Western blot
30 to 40 μg of proteins from denatured (100°C for 5
min) total extracts were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis together with
a molecular weight marker (Full Range Rainbow Mole-
cular Weight Marker, Amersham, Buckinghamshire,
UK), and transferred to a polyvinylidene difluoride
membrane (Millipore, Bedford, MA, USA). After wash-
ing in Tris-buffered saline (TBS: 20 mM Tris, 0.15 M
NaCl, pH 7.5) for 5 min, dipping in methanol for 10 s
and drying in air, the membranes were incubated with
the following primary antibodies overnight at 4°C: poly-
clonal rabbit anti-Kir 6.1 or polyclonal rabbit anti-Kir
6.2 (both 1:500, Alomone, Jerusalem, Israel), polyclonal
rabbit anti-inducible nitric oxide synthase (iNOS) (1:200,
Millipore, Bedford, MA, USA), polyclonal rabbit anti-
cyclooxygenase-2 (1:2000, Santa Cruz Biotechnology, St.
Cruz, CA, USA) and monoclonal mouse anti-b-actin
(1:50000, Sigma-Aldrich, St. Louis, MO, USA) diluted in
immunoblot buffer (TBS containing 0.05% Tween-20
and 5% non-fat dry milk). The membranes were then
washed twice in 0.05% Tween-20 in TBS for 15 s and
incubated with the following horseradish peroxidase
(HRP)-labeled secondary antibodies for 1 h at 23 to 25°
C: donkey anti-rabbit (1:5000, Amersham, Buckingham-
shire, UK) or goat anti-mouse (1:5000, Santa Cruz Bio-
technology, St. Cruz, CA, USA). After extensive washes
in 0.05% Tween-20 in TBS, they were incubated in
ECL-Plus (Amersham, Buckinghamshire, UK) for 5 min.
Membranes were then exposed to the camera and the
pixel intensities of the immunoreactive bands were
quantified using the percentage adjusted volume feature
of Quantity One 5.6.4 software (Bio-Rad Laboratories,
Hercules, CA, USA). Data are expressed as the ratio of
the band intensity of the protein of interest to the load-
ing control protein band (b-actin).
EAE induction and treatment
EAE was induced by immunization with > 95% pure
synthetic MOG35-55 peptide (rat MOG35-55, MEVG-
WYRSPFSRVVHLYRNGK; EspiKem Srl, Florence, Italy).
Mice were injected subcutaneously at one side of the
flank with 100 μL solution containing 150 μg of rat
MOG in complete Freund’s adjuvant (Sigma-Aldrich, St.
Louis, MO, USA) and 5 mg/mL Mycobacterium tuber-
culosis H37Ra (Difco Laboratories, Detroit, MI, USA).
Mice also received intraperitoneal injections of 150 ng
pertussis toxin (Sigma-Aldrich, St. Louis, MO, USA) in
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100 μL PBS immediately after MOG injection and 48 h
later. Mice were scored daily for signs of EAE on a scale
of 0 to 6 using the following criteria: 0, no clinical signs;
1, distal limp tail; 1.5, complete limp tail; 2, mild para-
paresis of the hind limbs, unsteady gait and impairment
of righting reflex; 3, moderate paraparesis, partial hind
limb paralysis, voluntary movements still possible and
ataxia; 4, paraplegia and forelimb weakness; 5, tetrapar-
esis; 6, moribund state. When clinical signs were inter-
mediate between two grades of the disease, 0.5 was
added to the lower score. To study the effects of the
drug, two different administration protocols were per-
formed: in the first one, treatment began on the first
day of EAE induction whereas the second one started
when the EAE clinical score was ≥ 1 (appearance of
clinical signs). The MOG-immunized mice were admi-
nistered either 0.8 mg/kg diazoxide (treated group) or
diluent (0.3% DMSO in water, vehicle group) for 30 or
15 days by oral gavage, respectively.
Blood glucose measurements
Blood glucose measurements were performed using an
Accu-Chek® Aviva glucometer (Roche Diagnostics,
Basel, Switzerland). Blood samples were obtained from a
small incision made at the distal part of the mice tail.
Blood glucose concentrations higher than 176 mg/dL
were considered hyperglycemic, according to animal
welfare guidelines.
Histological and immunohistochemical analysis
To analyze the efficacy of diazoxide during the chronic
effector phase of EAE, histological spinal cord analysis
was performed in animals treated from the appearance
of the first clinical signs. At the end of treatment, ani-
mals were anesthetized, transcardially perfused with 0.01
M PBS, followed by 4% paraformaldehyde solution.
Spinal cords were then collected and post-fixed in fresh
fixative solution for 4 h. For cryoprotection, they were
placed in 30% sucrose for 24 h. Tissue was frozen in
isopentane and dry ice and stored at -80°C. Coronal sec-
tions (20 μm) at the cervical, thoracic and lumbar levels
were obtained in HM550 Cryostat (Thermo Scientific,
Waltham, MA, USA) at -22°C and deposited onto poly-
L-lysine-coated microscope slides.
Hematoxylin and eosin (H&E), Luxol fast blue (LFB),
Nissl and Bielschowsky silver staining were used for his-
tological studies.
For immunohistochemical studies, sections were first
blocked in PBS (0.5% Triton) containing 10% goat serum
(Sigma-Aldrich, St. Louis, MO, USA) for 2 h. The sections
were then incubated with primary antibodies at 4°C over-
night, followed by secondary antibodies for 2 h in blocking
solution. The following antibodies were used: anti-Kir6.1
and anti-Kir6.2 (1:150 dilution, Alomone, Jerusalem,
Israel), anti-CD11b and anti-CD3 (1:400 and 1:300 respec-
tively, Serotec, Oxford, England, UK), anti-glial fibrillary
acidic protein (GFAP) (1:2000, Dako, Glostrup, Denmark),
anti-CD20 (1:300, Santa Cruz Biotechnology, St. Cruz, CA,
USA) and anti-Neuronal nuclei (NeuN) (1:500, Millipore,
Bedford, MA, USA). The secondary antibodies used were
Alexa®488 and 596 (from 1:2000 to 1:1000, Molecular
Probes, Invitrogen, Eugene, OR, USA). To assess the num-
ber of cells, the nuclear stain Hoechst 34580 (2 μg/mL;
Molecular Probes, Invitrogen, Eugene, OR, USA) was
added prior to final washes after secondary antibody addi-
tion. Sections were mounted using ProLong Gold antifade
medium (Molecular Probes, Invitrogen, Eugene, OR,
USA). As absolute controls, non-immunized healthy mice
were also analyzed.
Quantification of histology and immunohistochemistry
Images were captured using both wide field microsope
Leica AF7000 (Leica Microsystems GmbH, Wetzlar, Ger-
many) located at the Institut de Biologia Molecular de Bar-
celona, Microscopy Unit, Parc Científic de Barcelona, and
SP1 confocal microscope. The analyses were carried out
on three randomly selected sections of cervical, thoracic
and lumbar spinal cord per animal (n = 4 to 8 animals/
group) to assess demyelination, number of inflammatory/
infiltration lesions, reactive microglial-macrophage areas,
astrocytic reactivity and number of infiltrating cells. To
assess axonal loss area and for neuronal counting, the
thoracic region (n = 6 to 8 animals/group) was used.
The resulting area and cell measurements were quan-
tified using ImageJ software analysis (National Institute
of Health, USA). For astrocytic reactivity, after defining
the threshold for background correction, the integrated
density of GFAP labeling was measured. The integrated
density is the area above the threshold for the mean
density minus the background. All analyses were per-
formed blind with respect to the experimental groups.
Statistical Analysis
Data are expressed as the mean ± SEM unless specified.
Statistical analysis of cell treatments was carried out
using one-way ANOVA followed by Newman-Keuls
post test when three or more experimental groups were
compared. Data on the effect of EAE treatment on clini-
cal signs, histological and immunohistochemical analysis
were analyzed by Student’s t-test or Mann-Whitney test
for nonparametric data. Values of p < 0.05 were consid-
ered statistically significant.
Results
Expression and localization of KATP channels in microglial
cells
To confirm the presence of pore-forming Kir (Kir6.1
and Kir6.2) subunits of KATP channels we studied their
Virgili et al. Journal of Neuroinflammation 2011, 8:149
http://www.jneuroinflammation.com/content/8/1/149
Page 5 of 18
expression by western blot. Unstimulated and LPS+IFNg
stimulated primary microglia cultures and BV-2 cells
were analyzed. A strong signal for both subunits in all
conditions was observed (Figure 1A).
To determine the subcellular distribution of KATP
channels in BV-2 microglial cells, double immunofluor-
escence against the microglial membrane marker CD11b
and Kir6.1 or Kir6.2 were performed. Results showed
co-localization of CD11b and both Kir6.X subunits
immunosignal at membrane level as well as in the cyto-
sol (Figure 1B-G). These findings suggest a localization
of KATP channels to both plasma membrane and inter-
nal cellular components.
Diazoxide exerts an anti-inflammatory effect on microglia
in vitro without altering phagocytic capacity
Primary microglia cultures were used to study the ability
of diazoxide to inhibit the release of inflammatory sig-
nals. Microglia activation was induced with 100 ng/mL
LPS and 10 pg/mL IFNg, and the evaluation of the
inflammatory response was studied thought the measure
of NO production, and TNF-a and IL-6 release in the
media. Microglia cells showed an increase of NO pro-
duction and cytokines release 24 h after the LPS/IFNg
stimulation. Diazoxide pre-treatment before stimulation
decreased NO production (up to 38.8 ± 6.6%; Figure
2A) and TNF-a and IL-6 release (up to 25.0 ± 8.2% and
34.6 ± 5.1% respectively; Figure 2B-C) in a dose-depen-
dent manner. Unstimulated cells treated with diazoxide
100 μM showed no differences compared to control
cells (Figure 2A-C). Similar results were observed when
diazoxide was tested in BV-2 microglia and primary
mixed glial cultures, composed by 75% astrocytes and
25% microglia (data not shown).
Next, we evaluated iNOS and COX-2 expression in
microglial cultures by western blot. Diazoxide 100 μM
pre-treatment also inhibited induction of iNOS expres-
sion observed after LPS/IFNg stimulation, while no
effect on induction of COX-2 expression was detected
(Figure 2D-F).
We also studied the phagocytic ability of microglia by
measuring the uptake of fluorescent microspheres by
BV2 cells. Stimulation with LPS/IFNg for 24 h induced
an increase in the percentage of phagocytic cells when
compared to unstimulated microglia. This effect was not
modified when pre-treatment with 100 μM diazoxide
was performed (Figure 2G). The single-cell fluorescent
population was selected on a forward-side by flow cyto-
metry and phagocytosis of microspheres was represented
by the peaks at the high fluorescent levels (Figure 2H).
KATP channel pore-forming Kir subunit expression is
enhanced in activated microglia in EAE mice
To analyze the presence of KATP pore-forming Kir compo-
nents in EAE, double immunofluorescence staining against
neuronal (NeuN), astrocytic (GFAP) or microglial/macro-
phage (CD11b) specific markers and Kir6.1 or Kir6.2 were
performed. Spinal cord coronal sections from MOG35-55-
Figure 1 Western blotting show expression of both Kir6.1 and Kir6.2 KATP channel pore-forming subunits in unstimulated and LPS/
IFNg-stimulated BV-2 cells (A, left) and microglial primary cultures (A, Right). Staining for the microglial cell membrane marker CD11b
(B and E) and the KATP channel subunits Kir 6.1 (C) or Kir 6.2 (F) showed colocalization in BV-2 microglia, indicating the expression of
the KATP channel at the cytoplasmic membrane (D and G, white arrows). Control: unstimulated cells; L+I: cells stimulated with LPS and IFNg.
Scale bar = 30 μm.
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immunized EAE mice and non-immunized healthy control
animals were analyzed. Corresponding technical controls
and single immunofluorescence detection were carried out
for all situations. Strong Kir6.1 and Kir6.2 fluorescence
signals were observed in NeuN- and GFAP-positive cells
in spinal cord sections from both EAE and control mice
(data not shown). Low basal levels of Kir 6.1 and Kir6.2
were discernible in CD11b-positive cells, corresponding to
that in resting microglia of non-immunized control ani-
mals (Figure 3A-C). When spinal cord sections from EAE
mice were analyzed, colocalization of both Kir6.x subunits
and CD11b was observed in cells that displayed the char-
acteristic amoeboid morphology of activated microglia/
macrophages (Figure 3D-F for Kir6.2 and Additional File 1
Figure S1A-C for Kir6.1).
The quantities of Kir6.1 and Kir6.2 were examined by
Western blotting of total protein extracted from sacro-
lumbar and thoracic-cervical sections of spinal cords
from EAE and non-immunized mice. When protein
extracts from EAE and non-immunized healthy control
Figure 2 Anti-inflammatory effects of diazoxide pre-treatment in microglial cell cultures stimulated with LPS and IFNg. Nitrite
accumulation (A), and TNF-a (B) and IL-6 release (C) in control (unstimulated cells), DZX (unstimulated cells pretreated with 100 μM diazoxide),
diazoxide (DZX) and LPS/IFNg + Diazoxide (10 μM to 100 μM) normalized for LPS/IFNg untreated cells. Quantification of iNOS (D) and COX-2 (E)
protein expression in control, LPS/IFNg untreated cells and 100 μM diazoxide pre-treated LPS/IFNg cells. Protein expression was measured by
western blot and data normalized with b-actin. Images showing representative immunoblotting (F). Percentage of phagocytic cells quantificated
by fluorescent microspheres incorporation of control, LPS/IFNg untreated cells and 100 μM diazoxide pre-treated LPS/IFNg cells (G). One
representative phagocytosis experiment is shown (H,left). Phagocytosis of microspheres is represented by the peaks at the high fluorescence
levels (H,right) Control: unstimulated cells; DZX: unstimulated cells pretreated with 100 μM diazoxide; L+I: cells stimulated with LPS and IFNg; L+I
+DZX: L+I-stimulated cells pretreated with diazoxide. Results are shown as mean ± SEM of three to five independent experiments. *p < 0.05, **p
< 0.01, ***p < 0.001 vs L+I for A-E and vs control for G.
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animals were compared, no significant changes in the
Kir6.1 immunoblotting signal were observed (Additional
File 1, Figure S1D and E), whereas an increase in Kir6.2
expression was observed in the thoracic-cervical and
lumbar-sacral sections of spinal cord from EAE mice,
this observation was significant in the thoracic-cervical
section (Figure 3G-H).
Oral administration of diazoxide ameliorates clinical signs
in EAE mice
MOG35-55-immunized mice developed severe EAE, with
the onset of clinical signs occurring on days 10 to 13
after immunization. Symptoms peaked at days 13 to 16
and were followed by a stable chronic phase of the dis-
ease. To investigate the effects of diazoxide during the
Figure 3 Confocal double immunofluorescence images of CD11b (red, A and D) and Kir6.2 (green, B and E) in spinal cord sections
from healthy control mice (Ctrl) or MOG35-55 EAE mice. A slight intensity was found for Kir6.2 in healthy section showing low localization of
the KATP Kir6.2 subunit in CD11b-positive cells (white arrows, C). However, higher intensity of Kir6.2 subunit in CD11b reactive cells showing a
strong colocalization of both (white arrows, F) was observed. Western blotting for Kir6.2 in total protein homogenates from lumbar-sacral and
thoracic-cervical regions of the spinal cord from non-immunized control animals (control, G) and EAE mice (EAE, G) show an increase in Kir6.2
expression in EAE mice. This increase is statistically significant in the thoracic-cervical level of the spinal cord (H). Results are shown as mean ±
SEM. **p < 0.01 between control and EAE. Scale bar = 30 μm.
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chronic effector phase of EAE, diazoxide treatment began
at the onset of neurological symptoms (clinical score ≥ 1)
of EAE mice (days 10 to 13 post immunization). When
the clinical signs appeared, mice were randomly distribu-
ted into two groups and treated for 15 days with oral
diazoxide (0.8 mg/kg) or vehicle (0.3% DMSO in water),
respectively. The composite results of three independent
experiments are summarized in Figure 4A and Table 1.
Diazoxide-treated EAE mice showed an improvement in
the clinical signs of the disease when compared to vehi-
cle-treated animals (Figure 4A). The severity of the EAE
clinical score was significantly reduced from the seventh
day of treatment until the end of the study. In all three
experiments, diazoxide-treated mice showed a lower
mean EAE clinical score for the 15 days of treatment and
a lower maximal mean score than vehicle-administered
animals. When the area under the curve (AUC) was ana-
lyzed, a significant reduction was found in diazoxide-
treated mice (63.3 ± 2.6 vs 45.8 ± 5.6; p < 0.05; Figure
4B). At the end of the study, clinical examination of the
animals revealed that the majority of diazoxide-treated
mice presented weaknesses of the tail and hind limb,
whereas most vehicle-treated mice presented severe hind
limb paraparesis. In addition, some animals in the vehicle
group reached the moribund state (clinical score 6), but
this never occurred in the diazoxide-treated mice group.
Daily oral administration of diazoxide for 30 days
starting from the same day as immunization was also
examined. Treatment produced a significant ameliora-
tion of the EAE clinical score (Figure 4C) and global
EAE severity measured as AUC (49.4 ± 3.5 vs 34.2 ±
2.9; p < 0.01; Figure 4D). All animals immunized and
treated with either vehicle or diazoxide developed EAE.
To test whether the dose used to treat EAE mice
caused hyperglycemia, blood glucose levels were mea-
sured over a period of 30 days. Measurements were per-
formed before oral diazoxide (0.8 mg/kg) administration
(time 0) and after 30 and 60 min. No evidence of hyper-
glycemia was detected at any of the analyzed time points
(data not shown).
Figure 4 Diazoxide treatment improves clinical signs in the EAE model. Animals were orally administered with 0.8 mg/kg diazoxide or
vehicle (0.3% DMSO in water) at the onset of clinical signs (day 10-13 post immunization) (Score ≥ 1). Once the treatment started the animals
were orally treated for 15 days. A minimum of 7 mice per group was used in each experiment. Data show the mean of three independent
experiments (A) and AUC for each clinical score curve (B). Diazoxide treatment was also tested for 30 days by starting its administration on the
same day as that of the MOG35-55 immunization. Data show the daily score mean (C) and the AUC for each clinical score curve (D). Data are
represented as mean ± SEM. * p < 0.05, ** p < 0.01.
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Diazoxide treatment diminishes area of demyelination
and number of inflammatory lesions during the effector
phase of EAE
To examine EAE-associated demyelination and cell infil-
tration, histopatological studies were performed with
LFB and H&E staining, respectively.
LFB staining showed that the area of demyelination
was more pronounced in the spinal cord of vehicle-trea-
ted EAE mice than in those from diazoxide-treated EAE
animals (Figure 5A and 5C, respectively). The decrease
in the demyelination area in diazoxide-treated mice was
significant in the thoracic region and when the spinal
cord was analyzed globally, compared to the vehicle-
administered group (11.8 ± 3.7% vs 2.0 ± 0.8% and 7.8 ±
2.9% vs 3.3 ± 0.9%; p < 0.01 and p < 0.05, respectively;
Figure 5E).
H&E staining of consecutive spinal cord sections of
diazoxide-treated EAE mice showed a slight, but not sig-
nificant, decrease in the number of lesions when com-
pared to control EAE animals (Figure 5B, D and 5F).
However, the lesions were smaller and the integrity of
the tissue was better preserved in both white and gray
matter in the diazoxide-administered EAE animals.
Diazoxide treatment diminishes the astrocytic reactivity
and area of activated microglia/macrophage in the
effector phase of EAE
To assess the consequences of diazoxide administration
on astroglial reactivity, GFAP staining was performed.
Results showed that the spinal cords of diazoxide-treated
EAE mice exhibited less immunoreactive intensities than
vehicle-treated EAE mice (Figure 6A and 6B, respec-
tively) especially in gray matter. Fluorescent intensity
quantification showed a significant decrease of GFAP sig-
nal in diazoxide treated animals in cervical (1,47.106 ±
0,14. 106 vs 0,76.106 ± 0,10.106;p < 0.01; Figure 6C) and
thoracic region (2,43.106 ± 0,25. 106 vs 1,06.106 ±
0,26.106 ; p < 0.01; Figure 6C) and when the spinal cord
was globally analyzed (2,13.106 ± 0,09. 106 vs 1,12.106 ±
0,17. 106; p < 0.01; Figure 6C). The classical radial mor-
phology of GFAP-positive cells in spinal cord white mat-
ter was also better preserved in diazoxide-treated mice.
To determine the effects of diazoxide on microglial/
macrophage reactivity, areas of activated CD11b-positive
cells from different regions of the spinal cord were quan-
tified. Diazoxide-treated mice showed a smaller area of
reactivity than vehicle-administered EAE mice (Figure
6D and 6E, respectively). Image analysis showed a signifi-
cant reduction of CD11b reactive area in the thoracic
region and when the spinal cord was globally analyzed
(19.1 ± 4.4% vs 8.4 ± 1.6% and 16.25 ± 2.1% vs 8.9 ±
1.1%; p < 0.05 and p < 0.01 respectively; Figure 6F).
Diazoxide treatment reduces EAE-associated axonal loss
and improves neuronal integrity
Bielschowsky staining was used to identify and quantify
areas of axonal loss in the spinal cord of diazoxide-trea-
ted and vehicle-treated EAE mice. Diazoxide-adminis-
tered EAE mice showed a significant decrease in the
percentage of axonal loss when compared to vehicle-
treated EAE mice (1.3 ± 0.6 vs 8.3 ± 2.2; p < 0.01; Figure
7A and 7B).
To analyze the effect of diazoxide treatment on neuro-
nal cells, NeuN immunodetection and Nissl staining
were performed. NeuN immunoreactivity showed a
decrease in neuronal staining in vehicle-treated EAE
mice when compared to healthy controls, whereas no
differences were observed between healthy animals and
0.8 mg/kg diazoxide-treated EAE mice (Figure 7C). A
significant decrease (32%, p < 0.01) in NeuN-positive
cells in gray matter at the thoracic level was found in
vehicle-treated EAE mice compared to healthy mice.
Diazoxide-treated animals also showed a decrease in
NeuN-positive cells, but it was not significantly different
from that of healthy controls (Figure 7D). Nissl staining
confirmed neuronal preservation in the gray matter of
diazoxide-treated mice in contrast to samples from vehi-
cle-administered EAE mice (Figure 7C).
Table 1 Effects of diazoxide treatment on clinical signs during the effector phase of EAE mice
N° animals Mean clinical score Area under the curve (AUC)
N° EAE death Days of treatment Mean Maximal grade
Vehicle
Exp 1 11 1 15 3.1 ± 0.1 4.1 ± 0.4 43.9 ± 4.7
Exp 2 8 0 15 3.3 ± 0.2 4.4 ± 0.1 48.3 ± 2.0
Exp 3 7 1 15 3.5 ± 0.2 4.7 ± 0.2 56.0 ± 4.4
Diazoxide
Exp 1 11 0 15 1.9 ± 0.1*** 2.7 ± 0.3* 28.3 ± 4.4*
Exp 2 9 0 15 2.6 ± 0.1** 3.8 ± 0.2* 37.2 ± 3.1*
Exp 3 7 0 15 2.6 ± 0.1*** 3.5 ± 0.5* 36.9 ± 5.1*
Summary of three independent experiments. During the effector phase of EAE, 0.8 mg/kg diazoxide significantly reduced the mean global score, maximal grade
and area under the curve when compared to untreated mice. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5 Representative Luxol fast blue histochemical staining for myelin in coronal sections of spinal cords from vehicle- and
diazoxide-treated mice (A and C, respectively). Quantification of the percentage of white matter area not stained by LFB shows a decrease
in demyelination in diazoxide-treated mice (E). This effect was significant in the thoracic region and when the spinal cord was analyzed globally.
H&E staining shows typical cell infiltrations and tissue lesions in spinal cords of vehicle- and diazoxide-treated animals (B and D, respectively).
Upon quantification, results show a decrease of inflammatory lesions in all spinal cord regions (F). Results are expressed as mean ± SEM. n
(animals) per group ≥ 6. Slices analyzed per animal and section ≥ 3. * p < 0.05, **p < 0.01. Scale bar = 100 μm.
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Diazoxide oral treatment does not reduce lymphocytic
infiltration into the spinal cord during EAE
To determine whether diazoxide treatment affected T
and B lymphocyte infiltration into the spinal cord of
EAE mice, immunoflorescence using anti-CD3 and anti-
CD20 antibodies was performed. Cell counting demon-
strated no differences in the number of CD3- or CD20-
immunopositive cells between vehicle-treated and diaz-
oxide-treated animals (Figure 8A-F). A lower area of
infiltration was observed in diazoxide-treated mice, cor-
responding to the smaller damaged areas observed in
these animals.
Discussion
KATP channels are well known as linkers between cell
metabolism and membrane potential. This activity has
been classically described in pancreatic beta-cells, where
an increase in plasma glucose promotes a calcium-
dependent release of insulin due to the closing of KATP
channels as a result of glycolysis-mediated increases in
cytoplasmic ATP levels. KATP channels have also been
described in the mitochondria, located on the inner
membrane of these organelles where they play a crucial
role in the maintenance of mitochondrial homeostasis
and the proton gradient involved in the respiratory
chain [30].
Besides pancreatic beta-cells, physiologically functional
KATP channels have been described in numerous cell
types such as myocytes, neurons, astrocytes and oligo-
dendrocytes [31-33]. In recent years, the expression of
these channels in microglial cells has also been reported
[17,20]. Whereas Zhou and colls. only asserted the pre-
sence of SUR2 and Kir6.1 in microglial mitochondria in
vitro, Ramonet and colls. demonstrated the expression
Figure 6 Representative images of GFAP immunostaining of spinal cord sections from vehicle- and diazoxide-treated EAE mice (A and
B, respectively). Upon quantification of fluorescent signal in the gray matter, results show a decrease of GFAP intensity in cervical and thoracic
region and when the spinal cord was globally analyzed in diazoxide treated animals (C). CD11b immunolabeling of spinal cord sections of
vehicle- and diazoxide-treated EAE mice (D and E, respectively) allows the identification of reactive microglia/macrophages in white matter as
regions with ameboid-shaped cells (D bottom, image magnification) in contrast to the resting state (E bottom, image magnification). Upon
quantification, results show a smaller area of reactivity in diazoxide-treated mice when compared to vehicle treated EAE mice (F). This effect was
statistically significant when the thoracic level and the spinal cord was globally analyzed. Results are expressed as mean ± SEM. n (animals) per
group ≥ 4 for GFAP immunoreactivity and n (animals) per group ≥ 6 for area of microglia/macrophages reactivity. Slices analyzed per animal
and section ≥ 3. *p < 0.05, **p < 0.01. Scale bar = 100 μm.
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of SUR1 as well as SUR2 in microglia in vivo. In the
present study, we found in vitro and in vivo inmunor-
eactivity for Kir6.1 in microglia and also a clear positive
signal for Kir6.2. Moreover, using a specific fluorescence
antibody for the KATP channel Kir6.X subunits and for
the microglial cell membrane marker CD11b, we found
that KATP channels were not restricted only to the mito-
chondria of BV-2 microglial cells. Our hypothesis is that
microglial cells present functional KATP channels at
both mitochondrial and cytoplasmic membranes.
Further studies are needed to analyze their functional
cellular localizations in order to understand how com-
pounds that regulate the activity of this channel affect
microglial behavior.
In this way, compounds that can regulate ionic influx
in microglia could represent a novel therapeutic
approach for the treatment of CNS pathologies asso-
ciated with microglial-mediated neuroinflammation,
including EAE. In the present study, we demonstrated
that diazoxide inhibited microglial inflammatory activity
in vitro, coincidently with other authors [20,34]. Diazox-
ide treatment partially inhibited the inflammatory pat-
tern induced by LPS/IFN-g in microglial cells, inducing
a decrease in NO production that could be because of
the decreased expression of iNOS detected. We also
observed a decrease of two major inflammatory cyto-
kines IL-6 and TNF-a release. These pro-inflammatory
agents have been shown to mediate the neurotoxic
effects of reactive glial cells in vitro, and the inhibition
of their production has been shown to protect against
the neurotoxicity induced by reactive glial cells [35,36].
For example, expression of inducible iNOS is abundant
Figure 7 Representative Bielschowsky stained spinal cord sections at the thoracic level of vehicle- and diazoxide-treated EAE mice (A).
Quantification of silver staining of axons shows a decreased area of axonal loss in diazoxide-treated animals when compared to vehicle- EAE
mice (B). Split image of gray matter thoracic spinal cord sections with Nissl staining and NeuN immunolabeling derived from healthy control
mice (NO EAE), vehicle-treated EAE mice (VEHICLE) and 0.8 mg/kg diazoxide-treated EAE mice (DIAZOXIDE). Bottom panel shows higher
magnification of neuronal integrity in the posterior (NeuN) and anterior (Nissl) section of the spinal cord (C). Upon quantification of neurons in
the entire delineated gray matter, NeuN-immunolabeled neurons significantly decreased by nearly 32% in vehicle-treated EAE mice when
compared to normal controls, whereas no statistically significant differences were observed between diazoxide-treated animals and normal
controls (D). Results are expressed as mean ± SEM. n (animals) per group ≥ 6. Slices analyzed per animal and section ≥ 3. *p < 0.05, **p < 0.01.
Scale bar = 100 μm for A,B and C (upper panel). Scale bar = 45 μm for C (bottom panel).
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Figure 8 Immunofluorescence staining for CD3 and CD20 in spinal cord slices from vehicle-administered (A and B, respectively) and
diazoxide-treated EAE mice (C and D, respectively). Bottom panel shows higher magnification of CD3-positive cells (C). Upon quantification,
no significant differences between vehicle- and diazoxide-treated mice were observed for the numbers of CD3- and CD20-positive cells in any of
the spinal cord regions analyzed (E and F, respectively). Results are expressed as mean ± SEM. n (animals) per group ≥ 6. Slices analyzed per
animal and section ≥ 3. Scale bar = 100 μm.
Virgili et al. Journal of Neuroinflammation 2011, 8:149
http://www.jneuroinflammation.com/content/8/1/149
Page 14 of 18
in EAE and at the edges of MS lesions and NO is one of
the main effectors of demyelination [37,38]. Microglial
IL-6 secretion during EAE has been directly associated
to neuronal damage [39] and leukocyte activation within
the CNS [40]. TNF-a increases severity of EAE, chronic
macrophage/microglial reactivity, and demyelination
[41] and its inhibition prevents clinical disease despite
activated T cell infiltration to the central nervous system
[42] and promotes axon preservation and remyelination
[43].The absence of any significant effect of diazoxide
on COX-2 expression could be explained by the pre-
sence of different contributors in the final regulation of
COX-2, TNF-a, IL-6 and iNOS genes under inflamma-
tory stimuli [44,45]. Furthermore, our results showed
that diazoxide had no effect on microglial phagocytosis
in vitro. Since the clearance of debris by microglia is a
primordial step for the reparative process in the spinal
cord following an autoimmune attack [46,47], the main-
tenance of a phagocytic microglial phenotype with sup-
pressed inflammatory behavior could be an interesting
feature in demyelinating diseases. Because activated
microglia (and macrophages) could exert a neuroprotec-
tive role and promote remyelination [48,49], modulation
of microglia behavior would be more interesting than a
total inhibition of their activation for the treatment of
these diseases.
KCOs can decrease rotenone-induced mitochondrial
depolarization and p38/c-Jun N-terminal kinase activa-
tion in microglia [20] by acting at the mito-KATP chan-
nel level but the mechanisms involved with cytoplasmic
membrane KATP channels, which include changes in
membrane potential and calcium influx, are yet to be
elucidated. Recent studies have shown that the inhibi-
tion of N-type voltage-gated calcium channels reduced
the severity of EAE neurological symptoms and
decreased demyelination and infiltration areas [50,51].
The authors indicated microglia/macrophages as the
principal effectors of this improvement, demonstrating
that inhibition of these voltage-gated calcium channels
regulates microglial activation.
Although the action of KCOs on microglia would be
sufficient to explain the improvements observed in EAE
mice after diazoxide treatment, the presence of func-
tional KATP channels in other glial cells and neurons
could explain additional positive CNS effects induced by
KCOs, especially diazoxide. In astrocytes, diazoxide
exerts a neuroprotective effect by different mechanisms,
including the facilitation of glutamate uptake [52] and
amelioration of mitochondrial and connexin 43 dysfunc-
tion [53]. We also observed a decrease in nitrite produc-
tion and inflammatory cytokines release in primary
cultures that included both astrocytes and microglia and
a decrease of GFAP reactivity in the gray matter of diaz-
oxide treated EAE mice. In oligodendrocytes, diazoxide
has been reported to stimulate oligodendrocyte precur-
sor cell proliferation in a calcium-dependent manner as
well as promoting myelination in vivo and preventing
hypoxia-induced periventricular white matter injury
[33]. In neurons, the positive actions of diazoxide on
cell survival after cytotoxic and hypoxic/ischemic insult
have been well described [19,54-57]. Moreover, a recent
study in a triple transgenic mouse model of AD has
demonstrated the beneficial effect of diazoxide on the
improvement in cognitive tasks, reduction of anxiety,
decrease in the accumulation of amyloid-beta oligomers
and hyperphosphorylation of tau proteins [58]. Diazox-
ide may also exerts neuroprotective effects indepen-
dently of K+ channel activation by decreasing neuronal
excitability and activation of N-methyl-D-aspartate
(NMDA) receptors [18] or by increasing currents trough
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors [59]. The possibility of diazoxide
binding to other ion channels composed by SUR subu-
nits despite of KATP channels [60,61] should not to be
discarded and would need future research.
Taken together, these results reinforce our findings
and could explain the differences observed between
diazoxide-treated and untreated EAE mice, which
included improvements in the neurological score, axon
preservation and neuronal survival in addition to a
decrease in glial reactivity and myelin loss.
Diazoxide-treated animals showed a decrease in dis-
ease severity a few days after the first clinical signs were
observed, corresponding to the acute inflammatory
phase of the disease [62]. Interestingly, we did not
observe any changes in the number of infiltrating lym-
phocytes in the spinal cord of diazoxide-treated EAE
mice when compared to vehicle-treated ones. Further-
more, the appearance of EAE signs was not prevented
by diazoxide pretreatment, suggesting that oral treat-
ment with diazoxide has no effect on the first steps of
the pathology that include auto-antigen recognition,
adaptive immune response and lymphocyte [63,64].
However, the effect of diazoxide on the immune system
should be further explored, including direct actions of
the compound on lymphocytes and peripheral macro-
phage populations as well as the distribution of leuko-
cyte subpopulations during the course of EAE.
Diazoxide could diminish autoimmune attacks on white
matter by inhibiting microglial cells, without altering the
initial immune response and infiltration regulating the
pro-inflammatory environment and intercellular
interactions.
Conclusion
Daily oral administration of diazoxide in EAE mice dur-
ing the effector phase of the disease reduced the severity
of the clinical signs without any apparent adverse effect.
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Histological studies revealed that diazoxide decreased
demyelination and axonal loss, reduced tissue damage,
inhibited microglial/macrophage and astrocytic activa-
tion and preserved neuron integrity. No effects were
observed on the number of B and T lymphocytes infil-
trating the spinal cord.
We demonstrated the presence of KATP channels in
microglia and that its pharmacological activation pro-
duces an anti-inflammatory effect on reactive microglial
cells. Diazoxide treatment of LPS and IFNg-activated
microglial cells reduced NO, IL-6 and TNF-a produc-
tion as well as iNOS expression. COX-2 expression and
phagocytosis showed not to be altered by diazoxide
treatment.
We conclude that oral administration of diazoxide
constitutes an appropriate therapeutic approach for
treating MS and other demyelinating diseases involving
neuroinflammation and neurodegeneration.
Additional material
Additional File 1: Figure S1. Confocal double immunofluorescence
images of CD11b (red, A) and Kir6.1 (green, B) in spinal cord sections
from MOG35-55 EAE mice. Colocalization of Kir6.1 subunit in CD11b
reactive cells (white arrows, C) was observed. Western blotting for Kir6.1
in total protein homogenates from lumbar-sacral and thoracic-cervical
regions of the spinal cord from non-immunized control animals (control,
D) and EAE mice (EAE, D). Results showed no differences in Kir6.1
expression between control and EAE mice (E). Results are shown as
mean ± SEM. Scale bar = 30 μm.
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